Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03093909
Recruitment Status : Recruiting
First Posted : March 28, 2017
Last Update Posted : May 23, 2019
Sponsor:
Collaborators:
James B. and Lois R. Archer Charitable Foundation
Gateway for Cancer Research
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.

The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body.

The safety and side effects of this drug will also be studied.

This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work.

Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.


Condition or disease Intervention/treatment Phase
Malignant Neoplasm of Bone and Articular Cartilage Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Independent (Primary) Multiple Sites Malignant Neoplasms of Lip Oral Cavity and Pharynx Malignant Neoplasm of Male Genital Organs Malignant Neoplasms of Mesothelial and Soft Tissue Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma Malignant Neoplasms of Thyroid and Other Endocrine Glands Malignant Neoplasms of Urinary Tract Melanoma and Other Malignant Neoplasms of Skin Drug: Gemcitabine Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Actual Study Start Date : November 22, 2017
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Aerosol Gemcitabine (GCB)

Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).

Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.

Participants may continue to receive the study drug for up to 12 cycles per decision of doctor.

Drug: Gemcitabine
Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
Other Names:
  • GCB
  • aerosol gemcitabine
  • Aerosolized GCB




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) Recommended for Phase 2 Dose of Aerosol Gemcitabine (GCB) [ Time Frame: 4 weeks ]

    MTD is defined as highest dose level with six patients with at most 1 dose limiting toxicity (DLT) occurring during cycle 1. Dose levels will continue to be increased until 1 participant experiences DLT. If only 1 of 3 participants experiences DLT, 3 additional patients will be entered.

    Dose escalation conducted via accelerated titration method for first 2 dose levels followed by 3+3 method for remaining dose levels. Cohorts of 1 participant per dose level for first 2 dose levels. If at any time during cycle 1 there is an instance of pulmonary grade 2 toxicity or pulmonary function tests (PFT) decline>10% related to study drug, current dose level expanded to 3 participants & switched to 3+3 design. If neither of these nor any other DLT occur in dose levels 1-2, switch will be to the 3 + 3 design beginning with dose level 3. Three participants will be treated at dose level 3, if still no DLT, 3 more treated at dose level 4.


  2. Toxicities of Aerosol Gemcitabine (GCB) [ Time Frame: Reviewed with each 4 week cycle, up to 24 weeks for six dose levels ]

    Dose limiting toxicities associated with the MTD of aerosol GCB using the NCI Common Terminology Criteria version 4 for Adverse Events (CTCAE) will be utilized for AE reporting. DLT defined as any of the following events that are at least (possibly, probably or definitely) attributable to aerosol GCB. The observation period for the purposes of dose-escalation will be the first cycle of therapy.

    DLT Definition includes:

    • Any episode of respiratory (bronchospasm, cough and/or dyspnea) grade 2 toxicity.
    • or > 10% decrease in FEV1 that persists > 3 days after the drug is stopped or recurrent episode of respiratory (bronchospasm, cough and/or dyspnea) grade 2 toxicity.
    • Any grade 3 or 4 non-hematological toxicity.
    • Any grade 4 neutropenia or thrombocytopenia.


Secondary Outcome Measures :
  1. Assessment of Serum Levels of Aerosol Gemcitabine (GCB) [ Time Frame: Day 1 of therapy ]
    Assessment of serum levels of Gemcitabine (GCB) for evidence of spillover into the circulation and correlate with presence or absence of toxicity.

  2. Response of Serum Levels of Aerosol Gemcitabine (GCB) [ Time Frame: Baseline, end of Cycles 2, 4, and 6, and then every 3 cycles up to 30 days after study dose stopped. Cycles are 28 days. ]
    Response evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with diagnosis of solid tumor with lung metastases and patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
  2. Willing to comply with protocol therapy and required safety monitoring (self-report, pulse oximetry, remote spirometry, labs).
  3. Adequate organ function as defined by: peripheral absolute neutrophil count (ANC) >/= 1,000/mm3, platelet count >/= 100,000/mm3 (transfusion independent defined as not receiving platelet transfusions within a 7 day period prior to enrollment), hemoglobin >/= 8.0g/dl (may receive RBC transfusions), renal-creatinine </= 2 x ULN; hepatic- bilirubin and AST </= 5x ULN; pulmonary: FVC >/=50% predicted, Oxyhemoglobin saturation at rest >/=95% (off supplemental oxygen).
  4. Patient age >/= 12 years and </= 50 years.
  5. Performance Status: ECOG </= 2 for patients >/= 16 years old or Lansky play >/= 60% for patients </=15 years old.
  6. Patients must have resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to NCI CTCAE Grade </= 1 or to the baseline laboratory values as defined in the inclusion criteria.
  7. No radiotherapy within 2 weeks.
  8. Subjects who received GCB systemically previously are eligible for participation.

Exclusion Criteria:

  1. Currently being treated with bronchodilators or corticosteroids or known to have active asthma. This will not include patients who suffered from asthma as a child and outgrew it.
  2. Pregnant or breastfeeding women will not be entered into this study due to risks of fetal and teratogenic adverse events as seen in animal studies. Pregnancy tests must be obtained in females who are post-menarchal and of child bearing potential (e.g. female that has not been amenorrheic for at least 12 consecutive months or surgically sterilized). Males or females of reproductive potential will not participate unless they have agreed to use effective contraception for the entire period in which they are receiving protocol therapy and for at least one month after treatment ends. Effective contraception is defined as intrauterine device (IUD), hormonal (birth control pill, injections, implants, patch), tubal ligation and partner's vasectomy. Abstinence is an acceptable method of birth control.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bradycardia, related to cardiac disease, bundle branch block, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  4. Subjects with baseline symptoms of fever and/or cough and/or shortness of breath and/or wheezing and/or fatigue grade >/= 2 (CTCAE v4.0).
  5. Patients receiving other concurrent cancer therapy including chemotherapy, immunotherapy, or biologic therapy.
  6. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE Grade </= 1 with the exception of alopecia and laboratory values listed per the inclusion criteria. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (eg, hearing loss).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03093909


Contacts
Layout table for location contacts
Contact: Najat C. Daw-Bitar, MD 713-792-3280 ndaw@mdanderson.org

Locations
Layout table for location information
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
James B. and Lois R. Archer Charitable Foundation
Gateway for Cancer Research
Investigators
Layout table for investigator information
Principal Investigator: Najat C. Daw-Bitar, MD The University of Texas MD Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03093909     History of Changes
Other Study ID Numbers: 2015-0720
G-16-300 ( Other Grant/Funding Number: Gateway for Cancer Research )
NCI-2018-01314 ( Registry Identifier: NCI CTRP )
First Posted: March 28, 2017    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by M.D. Anderson Cancer Center:
Solid Tumors and Pulmonary Metastases
aerosol gemcitabine
aerosol GCB
Lung metastases
osteosarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Genital Neoplasms, Female
Genital Neoplasms, Male
Urologic Neoplasms
Bone Neoplasms
Lip Neoplasms
Thyroid Neoplasms
Skin Neoplasms
Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Urogenital Neoplasms
Genital Diseases, Male
Bone Diseases
Musculoskeletal Diseases
Mouth Neoplasms
Head and Neck Neoplasms
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Thyroid Diseases
Skin Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents